Summary Even though the majority of patients with bladder malignancies initially present with low stage disease, the clinical epidemiology of these so-called superficial bladder tumours is not well known. In this paper, disease characteristics at initial presentation and during follow-up are described in 1,745 primary cases documented prospectively in the Netherlands. The risk of recurrent disease after primary treatment is very high: in 60% of cases, at least one recurrence is diagnosed within 5 years (95% CI: 58-62% Society, 1991). Therefore, the greatest concern in these patients is not to reduce mortality but to lower and postpone the number of recurrences (which are very common in superficial TCC) and thereby to prevent progression to invasive disease (Herr, 1991 (and document) at least four random quadrant biopsies in macroscopically normal-looking urothelium (left and right lateral wall, trigone and dome) at the time of resection of the tumour(s). The therapy to be applied was transurethral resection of the tumour (TUR) in all patients. Urologists were advised to consider adjuvant intravesical instillations with chemotherapy or BCG vaccine in the case of multiple tumours. In pTI grade 3 patients more aggressive therapy, such as radical surgery or external or interstitial radiotherapy, would have to be considered. To detect recurrences, cystoscopy and urine cytology were used every 3 months in the first year after treatment. From the second year onwards, this check-up was performed every 6 months. Follow-up data concerning disease and life status were collected for each patient once every year.
Bladder cancer is a heterogeneous disease with an unpredictable clinical course. In urology practice, bladder cancer cases are differentiated on the basis of the extent of bladder wall invasion. The largest group is the group of superficial transitional cell carcinomas (TCC). Patients with superficial TCC have a fairly good prognosis with a 5-year relative survival of 80% to 90% (American Cancer Society, 1991) . Therefore, the greatest concern in these patients is not to reduce mortality but to lower and postpone the number of recurrences (which are very common in superficial TCC) and thereby to prevent progression to invasive disease (Herr, 1991) . To (Cox, 1972) .
Although the case series in this documentation project is large, registration was not population based, which implies that incidence rates cannot be calculated from the project. However, nine Comprehensive Cancer Centres in the Netherlands keep population based regional cancer registries (IKL), covering a population of approximately 850,000 in the southern part of the Netherlands, has complete data on the incidence of superficial bladder cancer since 1986 (Schouten et al., 1992) . Information from this registry from the period 1986-1989 was used to calculate age and sex-specific incidence rates. The population based cancer registry was also used to check whether patient intake in the documentation project was selective in any way. There appeared to be hardly any difference in age, sex, stage and grade distribution between the cancer registry and our case series, indicating no under or over representation in our series.
Results

Incidence
In the southern part of the Netherlands, the total bladder cancer incidence rate per 105 person-years (age-standardised to the European standard population) is 36.3 for males and 6.7 for females. Superficial bladder cancer incidence rates for males and females are 23.7 and 3.9, respectively. This accounts for 65% of the total bladder cancer incidence in males and 58% in females. The proportion of all bladder cancers diagnosed as superficial disease is higher in the younger age categories than in the older ones (Figure 1 ). In males, the lifetime risk of developing bladder cancer (before the age of 75 years) is 2.8%. The risk of superficial bladder cancer is 1.9%. In females, these risks are 0.5% and 0.4%, respectively.
Initial presentation
In the documentation project, 1,745 patients with superficial (pTa or pTl) TCC were registered. Characteristics of this group of patients at initial presentation are listed in Table I: H .4 .
. , . 4 32% of all the patients had a pTI tumour; 16% of the tumours were classified with differentiation grade 3 and 29% had multiple tumours. Random biopsies of macroscopically normal-looking urothelium were taken in 1,044 patients. In 22% of these patients, dysplasia or carcinoma in situ was diagnosed in at least one biopsy specimen. The median age at the time of diagnosis was 67 years. There was a clear shift towards a higher disease stage with increasing age (Figure 2 ). In patients under the age of 40 years, pTa grade 1 or 2 disease accounted for more than 85% compared to only 52% in patients over 80 years of age. The proportion of patients diagnosed with multiple tumours was also different for these age groups: 13% vs 37%.
From the total group of patients, 64% were treated with transurethral resection only; additional intravesical instillations were administered in 32% of the cases and more extensive therapy was given in 4% of the cases (radiotherapy and/or cystectomy). The latter 4% were excluded from the analysis of the risks of recurrence and progression.
First recurrence The life-table (or actuarial) risk of recurrent disease after primary treatment in superficial bladder cancer was very high. Within 5 years, nearly 60% of all the cases had at least one recurrence ( Figure 3 ). A proportion of this group of patients with a recurrence were prone to having more recurrences. The risk of recurrent disease in the first year of follow-up was 33% (95% CI: 31-35%). In the second year of follow-up, this risk was as high as 47% among the patients who had already had recurrent disease, compared to only 18% of the patients without recurrence in the first year of follow-up.
The risk of recurrent disease in superficial bladder cancer was dependent on a number of prognostic indicators. In the univariate analyses, tumour stage (pTl vs pTa), degree of differentiation (grade 3 vs 2 vs 1), multiplicity (multiple vs solitary) and extent of the tumour (involvement of more than one bladder area vs 1 area) had statistically significant effects on the risk of recurrence (all log-rank tests yielded P values<0.001). In our study, the risk of recurrence was not significantly different in male and female patients (P = 0.56) and in patients younger and older then 70 years of age (P = 0.93). The risk in patients with concomitant dysplastic abnormalities in normal-looking urothelium was only slightly higher than the risk in patients without these abnormalities: 57% and 51%, respectively (P=0.10). Even though intravesical chemotherapy or BCG was applied more frequently in patients with a poor prognostic profile, adjuvant therapy proved to be effective for preventing recurrences. In the patients who were treated with TUR alone, the 3-year risk of recurrence was 55%, whereas this risk was 49% (P = 0.005) in the cases treated with intravesical instillations.
We subsequently re-evaluated all the factors in a multivariate proportional hazards regression model. In this model, we also adjusted for the potential distorting effect of adjuvant intravesical chemotherapy. The results remained practically the same compared to those from the univariate analyses. Tumour stage, grade, extent and multiplicity had statistically significant independent prognostic value regarding the risk of first recurrence (see Table II ). The administration of intravesical therapy reduced this risk. When analysed multivariately, however, the result of random biopsies had no significant prognostic value: the relative risk of urothelial dysplasia or CIS compared to normal urothelium was only 1.11 (95% CI: 0.89-1.39).
Patients with the most favourable prognostic profile may therefore be defined as those with a solitary pTa grade 1 tumour located in just one area. In our study cohort, 390 patients had such a favourable score on all four factors. The 3-year risk in this group of patients (20% of whom were treated with intravesical instillations) was 37%. In the prognostically least favourable group of 55 patients with multiple pTl grade 3 tumours located in more than one area, the 3-year risk was as high as 77%, even though 69% of these patients were treated adjuvantly.
Progression
In the documentation project, disease progression was defined as a shift to a higher stage category (or the development of metastases). The 3-year actuarial risk of progressive disease was 10.2% (95% CI: 8.6-11.8%). After 5 years, this risk had hardly increased: 13.3%. As is the case with the risk of recurrence, tumour stage, grade, extent and multiplicity appeared to have prognostic significance for the risk of pro- gression. Furthermore, the 3-year risk in patients older than 70 years was 12.7%, whereas this risk was only 7.4% in patients younger than 70 years of age (P =0.001). Concomitant intraurothelial dysplasia or CIS significantly increased the risk of progression. In patients with such abnormalities the risk was 21%, whereas this risk was only 7% in patients without dysplastic abnormalities (P<0.001). Contrary to the effect on recurrence, intravesical instillations did not lower the risk of progression. Because the group of patients who received adjuvant therapy had a poorer prognostic profile, the risk of progression in this group was even higher than in the patients treated with TUR alone (12% vs 8%).
Except for tumour extent, all the factors with prognostic value in the univariate analyses retained their statistically significantly quality in the multivariate regression model.
Survival
The actuarial risk of dying within 5 years after diagnosis was 25% (95% CI: 23-27%) (Figure 4 (Jordan et al., 1987; Pauwels et al., 1988; Richards et al., 1991) . Although the stage distribution is believed to be a better measure for comparison, different interpretations of the pT category by different pathologists are also possible (Abel et al., 1988a; Kurth et al., 1989; Parmar et al., 1989; Herr & Jakse, 1991 For comparison the Dutch population was given the same age and sex distribution as the study population Figure 4 Actuarial survival (%) in patients with superficial TCC of the bladder (with 95% confidence interval) compared to the Dutch population.
In the Danish case series, 7.9% of the pTa/pT1 patients had carcinoma in situ in the cold-cup biopsy specimens taken at the first presentation of disease. Another 15.4% showed atypia grade 2. In a study by Flamm and Dona, CIS was found in the quadrant biopsy specimens in 6% of 216 patients. Dysplasia was found in 18% (Flamm & Dona, 1989) . In our study, the corresponding percentages were 8.2 and 13.6, respectively. In a recent study by Solsona et al. (1991) , 48 out of the 306 patients with superficial bladder tumours had associated carcinoma in situ, but this high number was caused by the inclusion of random area as well as suspicious area biopsies.
Nearly 60% of all the patients in our study had at least one recurrence within 5 years; most of them within 2 years (2-year recurrence risk: 45%). In fact, the recurrence risk in superficial bladder cancer is so high that (as opposed to other cancer sites) a second occurrence of TCC in the bladder is always interpreted as a recurrence, although this is theoretically incorrect (Abel, 1988) . The recurrence risk is dependent on a number of prognostic factors (Abel, 1988; Lum & Torti, 1991 Society, 1991) . In a recent study in the United Kingdom, the 5-year survival in 150 pTa and 85 pTa patients was 80 and 69%, respectively (Gulliford et al., 1991) . Flamm and Havelec (1990) (Cutler et al., 1982) . By contrast, in a recent study of Abel et al. (1988a) , muscle tissue was present in 95% of the pTa/pTl biopsy specimens. Unfortunately, comparable information was not available in our project.
Another possible explanation for excess mortality is undertreatment. Especially multiple high grade tumours which extend into the lamina propria are often seen to progress to higher stage disease (Cutler et al., 1982; Pocock et al., 1982; Heney et al., 1983 (Heney, 1988; Flamm & Havelec, 1990; Newling, 1990; Soloway et al., 1990; Vogeli & Ackermann, 1990 seem to increase rather than decrease the 5-year risk of progressive disease. However, this finding was caused by the fact that more patients with a relatively poor prognosis received adjuvant therapy. In a proportional hazards model with sex, age, tumour stage, grade, multiplicity, random biopsy result and therapy, the relative risk of TUR-only vs intravesical instillations was 1.0 (95% CI: 0.7-1.3). Nevertheless, even though analysed multivariately, this finding has to be interpreted with caution because our study was not initiated to study therapy effects and therefore was not randomised. Furthermore, most of the patients in our study who were treated adjuvantly, received intravesical instillations with Doxorubicin or Mitomycin-C. Intravesical immunotherapy with Bacillus Calmette-Guerin RIVM, a strain produced by the Dutch National Institute of Public Health and Environmental Hygiene, was applied less frequently. Two recent studies give some indication that BCG may be more effective in preventing progression than the chemotherapeutical agents (Herr et al., 1988; Eure et al., 1992) . Also, at the present time t = n EORTC phase II study is going on in which a sequential combination of intravesical chemotherapy with Mitomycin-C and intravesical immunotherapy with BCG is evaluated in recurrent superficial TCC of the bladder. Possibly, in the near future such a combination regimen may appear to be effective in delaying or preventing disease progression.
In summary, we can conclude that even superficial TCC, as a distinct subgroup of bladder cancer, is a heterogeneous disease with an unpredictable clinical course. Even though some important indicators for future recurrences and progressive disease can be identified (such as tumour stage, grade and multiplicity), it remains a challenge to find more and stronger prognosticators which can more accurately predict the disease outcome in individual patients. Only then will it be possible to treat patients with a poor prognosis more aggressively and to avoid overtreatment of patients with a fairly good prognosis.
